A pioneering February 2025 trial by Zhong Nanshan’s team revealed that first-line camrelizumab (anti-PD-1) plus apatinib (VEGFR inhibitor) and chemotherapy achieved promising efficacy with manageable toxicity in ES-SCLC. This evidence concerns the gene KDR and small cell lung carcinoma.